Update shared on 29 Nov 2025
Fair value Increased 0.48%Coloplast’s analyst fair value estimate was revised slightly upward to DKK 688.67 from DKK 685.39. Analysts weighed recent price target changes along with minor adjustments to growth expectations and profit margins.
Analyst Commentary
Recent updates from Street research reflect a mix of optimistic and cautious perspectives on Coloplast’s near-term outlook, as analysts adjust their targets and expectations.
Bullish Takeaways- Bullish analysts have raised price targets, citing resilience in Coloplast's business amid sector pressures.
- They highlight the company's ability to sustain profit margins despite a challenging market environment.
- Ongoing incremental growth in core segments continues to underpin confidence in the firm’s long-term strategy.
- Recent upward target revisions suggest confidence in management’s ability to execute on growth initiatives.
- Bearish analysts note that price targets have been lowered in response to moderated expectations for earnings growth.
- Concerns remain about the pace of recovery in certain product lines, which could affect near-term valuation.
- Cautious views emphasize the risk of further margin pressure if cost inflation persists or competitive dynamics intensify.
- Some see the current valuation as full, leaving less room for upside absent further positive catalysts.
What's in the News
- The Board of Directors of Coloplast A/S has recommended a year-end dividend of DKK 18.00 per share, raising the total dividend for the year to DKK 23.00 per share. This is an increase from DKK 22.00 in the previous year (Key Developments).
- Coloplast A/S issued new earnings guidance for fiscal year 2025-2026, projecting approximately 7% organic revenue growth and about 7% EBIT growth in constant currencies (Key Developments).
Valuation Changes
- Fair Value Estimate has risen slightly to DKK 688.67 from DKK 685.39.
- Discount Rate has increased marginally to 6.11% from 6.08%.
- Revenue Growth Assumption has dipped slightly to 6.74% from 6.76%.
- Net Profit Margin has edged up to 20.79% from 20.77%.
- Future Price/Earnings (P/E) Ratio is virtually unchanged, now at 26.28x compared to 26.25x.
Have other thoughts on Coloplast?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.